Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05352828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Study acronym: ACTION
StatusActive, Not Recruiting
PhasePhase 1
Started2022-07-25
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 3, 2023 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.

Amendment record

Amended 4 times since 2022-04-24; most recent filed 2023-03-31. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-29.

2023-03-31
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v4
2022-09-27
Amendment Study Status, Contacts/Locations v3
2022-08-17
Amendment Study Status, Contacts/Locations v2
2022-06-27
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2022-04-24
Original filing
Trial Details
NCT Number NCT05352828
Lead Sponsor Tessa Therapeutics
Collaborators: Bristol-Myers Squibb
Conditions Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
Enrollment 15 participants
Start Date 2022-07-25
Primary Completion 2025-12-15 (estimated)
Study Completion 2037-12-15 (estimated)
Updated on ClinicalTrials.gov 2023-04-03